| Code | CSB-RA007690MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to IPH-5201, designed for research targeting ENTPD1 (ectonucleoside triphosphate diphosphohydrolase-1), also known as CD39. ENTPD1 is an ectoenzyme that catalyzes the hydrolysis of extracellular ATP and ADP to AMP, playing a critical role in purinergic signaling and immune regulation. By converting pro-inflammatory ATP into adenosine precursors, ENTPD1 contributes to immunosuppressive tumor microenvironments and has emerged as an important checkpoint in cancer immunity. Elevated ENTPD1 expression is observed in various malignancies and on regulatory T cells, where it suppresses anti-tumor immune responses.
IPH-5201 is a therapeutic antibody developed to block ENTPD1 activity, aiming to restore immune function within the tumor microenvironment by preventing adenosine generation. This biosimilar provides researchers with a valuable tool for investigating ENTPD1-mediated immune evasion mechanisms, studying purinergic signaling pathways, and exploring novel immunotherapeutic strategies. The antibody supports studies examining the interplay between metabolic regulation and immune checkpoint function in oncology and inflammatory disease models.
There are currently no reviews for this product.